MNOV

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Wall Street analysts forecast MNOV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNOV is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MediciNova Inc revenue for the last quarter amounts to 123.32K USD, decreased % YoY.

MediciNova Inc. EPS for the last quarter amounts to -0.06 USD, decreased -0.00 % YoY.

MediciNova Inc (MNOV) has 13 emplpoyees as of December 17 2025.

Today MNOV has the market capitalization of 72.74M USD.